The determination of metabolite M17 and its meaning for immunosuppressive cyclosporin therapy

Angiology

Volumn 49, Issue 4, 1998, Pages 307-314

  Khoschsorur, G ^a,b   Auer, T ^a   Lanzer, G ^a   Petritsch, P ^a   Holzer, H ^a   Tscheliessnigg, K H ^a  

^a UNIVERSITY OF GRAZ   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A [1 (3,8 DIHYDROXY 2 METHYLAMINO 4 METHYL 6 OCTENOIC ACID)]; CYCLOSPORIN A [4 LEUCINE];

ARTICLE; AUTOIMMUNITY; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; DRUG DETERMINATION; FLUORESCENCE POLARIZATION IMMUNOASSAY; HEART TRANSPLANTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; ORGAN TRANSPLANTATION; TREATMENT INDICATION;

EID: 0031945099     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331979804900409     Document Type: Article

References (24)

1. Lermaire M, Fahr A, Maurer G: Pharmacokinetics of cyclosporin: Inter- and infra-individual variations and metabolic pathways. Transplant Proc 22:1110-1112, 1990.
2. Van Buren D, Widemann CA, Ried M, et al: The antagonistic effect of rifampin upon cyclosporin bioavailability. Transplant Proc 16:1642-1645, 1984.
3. Christians U, Sewing KF: Cyclosporin metabolism in transplant patients. Pharmacol Ther 57:291-345, 1993.
4. Maurer G, Lemaire M: Biotransformation and distribution in blood of cyclosporin and its metabolites. Transplant Proc 18:25-34, 1986.
5. Wallemacq PE, Lhoest G, Dumont P: Isolation, purification and structure elucidation of cyclosporin metabolites in rabbit and man. Biomed Environ Mass Spectrom 18:48-56, 1989.
6. Brockmüller UJ, Jochimsen F, Keller F, et al: Cyclosporin metabolites and central nervous system toxicity. Lancet I:1223, 1988.
7. Davenport A, Wiil EJ, Davison AM, et al: Toxiciry of cyclosporin metabolites. Lancet II:333, 1988.
8. Kohlhaw K, Wonigeit K, Schafer O, et al: Association of very high blood levels of cyclosporin metabolites with clinical complications after liver transplantation. Transplant Proc 21:2232-2233, 1989.
9. Leunissen K, Baumann G, Bosman R, et al: Cyclosporin metabolites and nephrotoxicity. Lancet II:1398, 1986.
10. Wysocki GP, Gebhardt W, Kopsa H, et al: Fibrous hyperplasia of the gingiva: A side effect of cyclosporin A therapy. Oral Surg 55:274-278, 1983.
11. Schmidt JB, Gebhardt W, Kopsa H, et al: Does cyclosporin A influence sex hormone levels? Exp Clin Endocr 88:207-211, 1986.
12. Penn I, Brunson ME: Cancer after cyclosporin therapy. Transplant Proc 20:885-892, 1988.
13. Sewing KF, Christians U, Kohlhaw K, et al: Biological activity of cyclosporin metabolites. Transplant Proc 22:1129-1139, 1990.
14. Freed BM, Rosano TG, Lempert N: In vitro immunosuppressive properties of cyclosporin metabolites. Transplantation 43:123-127, 1986.
15. Khoschsorur G, Semmelrock HJ, Rödl S, et al: Rapid, sensitive high-performance liquid Chromatographic method for the determination of CyA and its metabolites M1, M17 and M21. J Chromatography 690:367-372, 1997.
16. Nattermann U, Steiner W, Land W: Vergleich der Klinischen Wertigkeit eines polyspezifischen und eines monospezifischen Assays zur postoperativen Ciclosporin-Bestimmung nach Nierentrans-plantation. Z Transplantationsmedizin, Sonderdruck, Nr. 4, 1990.
17. Rossano TG, Freed BM, Gerilli J, et al: Immunosuppressive metabolites of cyclosporin in the blood of renal allograft recipients. Transplantation 42:262, 1986.
18. Freed BM, Stevens C, Brooks C, et al: Assessment of the biological activity of cyclosporin metabolites using the human jurkat cell line. Transplant Proc 23: 980, 1991.
19. Kunzendorf U, Brockmöller J, Jochimsen F, et al: Immunosuppressive properties of cyclosporin metabolites. Lancet 1:734, 1989.
20. Moyer TP, Winkels J, Krom R, et al: Evalution of Abbott TDx monoclonal assay of cyclosporin in whole blood. Clin Chem 37:16-20, 1991.
21. Wang P, Meucci V, Simpson E, et al: A monoclonal antibody fluorescent polarization immunoassay for cyclosporin. Transplant Proc 22:1186-1188, 1990.
22. Tredger JM, Gonde CE, Williams R: Monitoring cyclosporin in liver-transplant recipients: Effects of clinical status on the performance of two monoclonal antibody-based methods. Clin Chem 38:108-113, 1992.
23. Lucey MR, Kolars JC, Merion RM, et al: Cyclosporin toxicity at therapeutic blood levels and cytochrome P450IIIA. Lancet 335:11-15, 1990.
24. Burckart GJ, Venkataramanan R, Ptachcinski RJ, et al: Cyclosporin pharmacokinetic profiles in liver, heart and kidney transplant patients as determined by HPLC. Transplant Proc 18:457-476, 1986.